Mangoceuticals
MGRX
6 hedge funds and large institutions have $148K invested in Mangoceuticals in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 4 closing their positions.
105% more capital invested
Capital invested by funds: $72K → $148K (+$75.7K)
0.03% more ownership
Funds ownership: 0.1% → 0.13% (+0.03%)
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$30.5K |
| 2 |
PI
PEAK6 Investments
Chicago,
Illinois
|
+$27.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCG
McCollum Christoferson Group
Amherst,
New York
|
-$9.26K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$5.36K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$4.77K |
| 4 |
BL
BFSG LLC
Irvine,
California
|
-$44 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $41.2K | +$5.8K | +1,253 | +16% |
|
2
Mercer Global Advisors
Denver,
Colorado
| $30.4K | – | – | – |
|
|
VF
3
Virtu Financial
New York
| $30K | +$30.5K | +6,580 | New |
|
|
PI
4
PEAK6 Investments
Chicago,
Illinois
| $26.9K | +$27.3K | +5,890 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $16.1K | +$11.9K | +2,567 | +267% |
|
6
Morgan Stanley
New York
| $3.15K | – | – | – |
|
|
MCG
7
McCollum Christoferson Group
Amherst,
New York
| – | -$9.26K | -2,847 | Closed |
|
|
XT
8
XTX Topco
George Town,
Cayman Islands
| – | -$5.36K | -1,623 | Closed |
|
|
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$4.77K | -1,467 | Closed |
|
|
BL
10
BFSG LLC
Irvine,
California
| – | -$44 | -13 | Closed |
|
MGRX Hedge Fund Activity: Q2 2024 in Review
6 of the 6,929 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q2 2024, worth a combined $148K — up 105% from $72K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MGRX and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $30.5K. The largest seller was McCollum Christoferson Group, exiting entirely with an estimated $9.26K sold.
- 6 institutional investors held Mangoceuticals (MGRX) as of Q2 2024, down from 8 in Q1 2024.
- Funds reported $148K of Mangoceuticals stock for Q2 2024, up 105% quarter-over-quarter.
- 2 funds opened new Mangoceuticals positions in Q2 2024 and 4 closed out, a net change of -2 holders.
- The largest Mangoceuticals buyer in Q2 2024 was Virtu Financial, an estimated $30.5K added.
- The largest Mangoceuticals seller in Q2 2024 was McCollum Christoferson Group, an estimated $9.26K sold.
Based on aggregated 13F filings for Q2 2024.